Skip to main content
. Author manuscript; available in PMC: 2016 Mar 17.
Published in final edited form as: Circulation. 2015 Jan 16;131(11):972–979. doi: 10.1161/CIRCULATIONAHA.114.014113

Figure 1.

Figure 1

Figure 1

A. Point prevalence of dabigatran and rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation. B. Point prevalence of dabigatran and rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation, by drug dose.

HHS Vulnerability Disclosure